BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33251143)

  • 1. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
    Liu C; Xu X; Yuan H; Zhang Y; Zhang Y; Song S; Yang Z
    Front Oncol; 2020; 10():580277. PubMed ID: 33251143
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
    Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tumour heterogeneity by
    Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
    Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
    Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
    Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of Early Changes in
    He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
    Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of 16α-
    Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
    J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
    Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
    Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
    Zhao Y; Liu C; Zhang Y; Gong C; Li Y; Xie Y; Wu B; Yang Z; Wang B
    Sci Rep; 2018 Sep; 8(1):14458. PubMed ID: 30262849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
    Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by
    Xie Y; Du X; Zhao Y; Gong C; Hu S; You S; Song S; Hu X; Yang Z; Wang B
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with
    Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N;
    Ann Oncol; 2024 Feb; ():. PubMed ID: 38423389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can
    Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
    World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.